Company intelligence / Profile preview

Anecova

Lausanne, Vaud, Switzerlandprnewswire.co.uk ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

Anecova has developed and commercialized the AneVivo device, a CE-marked intrauterine culture system that enables fertilization and early embryo development to occur within the maternal womb rather than in vitro. Clinical results include successful births using this technology. Multiple clinical trials have been conducted or are ongoing to assess safety, performance, and potential benefits of this more physiological ART approach.

Therapeutic areas: Women's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Collaborations with world-leading scientists and clinicians in ART; no specific major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on Anecova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anecova.

Explore the full profile